Psoriasis Market to Register Incremental Growth by 2034 ...

DelveInsight Business Research, LLP United States of America United Kingdom

Regenerative Medicine Market to Reach $37.27 Billion by ...

Meticulous Market Research Pvt. Ltd. United States of America United Kingdom

Merkel Cell Carcinoma Market to Grow Rapidly at a CAGR of ...

DelveInsight Business Research, LLP United States of America United Kingdom

Chronic Inflammatory Demyelinating Polyneuropathy Market ...

DelveInsight Business Research, LLP United States of America United Kingdom Ireland

Die Europäische Arzneimittelagentur hat eine zusätzliche ...

Takeda Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom

Uveitis Treatment Market Size is Estimated at $1.4 Billion ...

Fact.MR United States of America United Kingdom

Next Generation Complement Therapeutics Market worth $23.04 ...

InsightAce Analytic Pvt. Ltd United States of America United Kingdom

Nísia: Brasil vai ampliar oferta de doses contra a dengue ...

Brazil Nigeria

Takeda erhält FDA-Zulassung gemäß 510 für HyHubTM und ...

Takeda ( TSE:4502/NYSE:TAK ) gab heute bekannt dass die US-amerikanische Arzneimittelbehörde FDA (Food and Drug Administration) die 510(k)-Zulassung für HyHubTM und HyHubTM ...

Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton in Narcolepsy Type 1

Takeda Announces New Assignments of Directors

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide Showing Reductions in Phlebotomy Improved ...

Takeda and Nature Announce Call for Applications Now Open ...

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

JCB partners with PayXpert to expand in-store card acceptance ...

Tokyo London and Paris May 27 2025 - (JCN Newswire) - JCB and PayXpert a pioneering omnichannel payment services provider based in Europe and in the UK today announced a strategic ...

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton in People with Narcolepsy Type 1

Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

FW Stockach: Brand einer Absauganlage in einem holzverarbeitenden ...

Stockach - Wahlwies - Am 30.04.2025 um 13:03 Uhr wurde die Feuerwehr Stockach mit den Abteilungen Wahlwies Espasingen und Kernstadt mit dem Alarmstichwort B3 - Feuer in Gebäude ...

XORTX veröffentlicht Update zur Anfrage der FDA zum Typ-B-Meeting ...

XORTX Therapeutics Inc. / CA98420Q3061

XORTX gibt Erteilung eines europäischen Patents bekannt ...

XORTX Therapeutics Inc. / CA98420Q3061

FW Stockach: Übungswochenende Roter Heuberg 2025 auf dem ...

Stockach - Ein intensives Übungswochenende erlebten Feuerwehren aus ganz Baden-Württemberg der Schweiz und Liechtenstein sowie zwei Fahrzeuge der Bundeswehr auf dem Truppenübungsplatz ...

JCB and First Cash Solution Partner to Help Cardmembers ...

Tokyo London and Frankfurt Mar 18 2025 - (JCN Newswire) - JCB Japan's only international payment brand and First Cash Solution a leading integrated payment provider as a subsidiary ...

KI-gestützte Analysen könnten die neurologische Therapie ...

FireFly-KI-Tool soll Wirksamkeit von Hemostemix‘ ACP-01-Therapie bei Demenz objektiv prüfen

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

XORTX initiiert Gichtprogramm und NDA-Gespräche mit der ...

XORTX Therapeutics Inc. / CA98420Q3061

Stretto Inc., Fujimi Incorporated, and SBI Life with NuSummit Win Findability Sciences Global AI Awards 2025 for Pioneering AI-Driven Transformation

Celebrating the Legacy of Excellence and Innovation. Zydus ...

Celebrating the Legacy of Excellence and Innovation

Takeda Pharmaceutical Company Limited: Julie Kim Will Succeed ...

Takeda Pharmaceutical Company Limited / JP3463000004

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

Zelltherapien erfreuen sich einer immer größeren Beliebtheit. ...

Weltweiter Markt für Zelltherapie soll bis 2034 jährlich um 20% wachsen

JCB and DOJO partner to help cardmembers enjoy a more seamless ...

TOKYO & LONDON Jan 16 2025 - (JCN Newswire) - JCB Japan s only international payment brand, and DOJO, a London-based payment technology provider, today announced a strategic partnership to enhance JCB ...

JCB unveils a new e-book that empowers merchants and acquirers ...

JCB unveils a new e-book that empowers merchants and acquirers to harness growth drivers in the European region

Top 25 Best Places to Work in Europe for 2024 revealed

Best Places to Work

XORTX fügt seiner Pipeline ein Programm der Spätphase ...

XORTX Therapeutics Inc. / CA98420Q3061

Takeda Announces Approval of HYQVIA? 10% S.C. Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

Blackstone Announces Acquisition of Tokyo Garden Terrace Kioicho, Japan?s Largest Ever Real Estate Investment by a Foreign Investor

JCB to Enable Seamless Transactions on ETA Applications ...

TOKYO & LONDON Dec 12 2024 - (JCN Newswire) - JCB International Co Ltd the international operations subsidiary of JCB Co Ltd Japan's only international payment brand today ...

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

Japanese Furniture & Home Furnishing Retail Chain Nitori Plans to Open First Store in India at R City Mall, Mumbai in December 2024

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Takeda Pharmaceutical Company Limited: Notice of the Revised ...

Takeda Pharmaceutical Company Limited / JP3463000004

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

Zwischen Liebe und Zerstörung: WDR dreht neue Serie „Verlangen“. ...

Köln - Aktuell finden in Belgien die Dreharbeiten zur Serie „Verlangen“ statt.

Takeda Receives European Commission Approval for ADZYNMA?? as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura ...

Swasti The Health Catalyst?s Big Picture Film Festival: ...

The Big Picture Film Festival at Catalysing Social Impact 2024 featured screenings of 13 films

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline

Streaming kompakt

Was sich derzeit zu streamen lohnt - zum Beispiel die schwarze Komödie «Nur noch ein kleiner Gefallen».

GNW-Adhoc: Release Therapeutics gibt neuen CEO zur Förderung ...

GENF July 04 2024 (GLOBE NEWSWIRE) -- Release Therapeutics (?Release Tx oder ?das Unternehmen ) ein in Privatbesitz befindliches Schweizer BioMedTech- Unternehmen gab heute ...

GNW-Adhoc: Merus ernennt Dr. Fabian Zohren zum Chief Medical ...

UTRECHT Niederlande und CAMBRIDGE Massachusetts July 01 2024 (GLOBE NEWSWIRE) -- Merus N.V. (https://merus.nl/) (Nasdaq: MRUS) (?Merus , das ?Unternehmen ?wir oder ?unser ...

GNW-Adhoc: Corza Medical schließt Übernahme des TachoSil-Produktionsbetriebs ...

WESTWOOD Massachusetts July 01 2024 (GLOBE NEWSWIRE) -- Corza Medical (https://corza.com/) hat die zuvor angekündigte Übernahme des TachoSil- Produktionsbetriebs in Linz ...

Takeda Announces New Assignments of Directors

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor

Takeda?s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo ...

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS? Combination in Frontline Hodgkin Lymphoma

Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer?s Disease

Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion

Takeda Pharmaceutical Company Limited: Takeda Announces ...

Takeda Pharmaceutical Company Limited / JP3463000004

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab a Potential Best-in-Class Anti-CD38 Monoclonal Antibody for Primary Immune Thrombocytopenia ...

Hape Kerkeling macht sich am Tag der Seltenen Erkrankungen ...

Hape Kerkeling macht sich am Tag der Seltenen Erkrankungen stark für die Waisen der Medizin / Spezialfolge des Podcasts Unglaublich krank

ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

GNW-Adhoc: Accumulus Synergy startet mit Spannung erwartete ...

BURLINGAME, Kalifornien, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Accumulus Synergy, Inc.

Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products

EQS-News: Der Future of Health Grant gewinnt mit Unisanté ...

Der Future of Health Grant gewinnt mit Unisanté einen zehnten starken Partner CSS Kranken-Versicherung AG / Schlagwort(e): Sonstiges Der Future of Health Grant gewinnt mit ...

Avec l arrivée d Unisanté le Future of Health Grant s ...

CSS Kranken-Versicherung AG

Con l'arrivo di Unisanté il Future of Health Grant si arricchisce ...

CSS Kranken-Versicherung AG

Der Future of Health Grant gewinnt mit Unisanté einen zehnten ...

CSS Kranken-Versicherung AG

The world’s 30 Best Places to Work for 2023 revealed

Best Places to Work

Takeda Receives Positive CHMP Opinion for HYQVIA? as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners

Global Healthcare Leaders Advance Sector Decarbonisation Ahead of COP28

Takeda?s ADZYNMA Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura ...

Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279 an Investigational Oral Once-Daily TYK2 Inhibitor in Patients with Active Psoriatic Arthritis at American ...

NurExone Biologic: Hoffnung für Millionen bei Rückenmarksverletzungen ...

Dr. Reuter Investor Relations / DE0000000014

Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance

Takeda berichtet Verkauf seiner Atemwegstherapeutika-Sparte ...

Takeda Pharmaceutical Company Limited (TOKYO:4502) hat heute den Abschluss des Vertrags zum Verkauf seiner Atemwegstherapeutika-Sparte an AstraZeneca berichtet.

Takeda Pharmaceutical Company Limited (TOKYO:4502) hat heute den ...

Takeda berichtet Verkauf seiner Atemwegstherapeutika-Sparte an AstraZeneca.

Takeda. ISIN: JP3463000004 WKN: 853849

Takeda

Takeda. ISIN: JP3463000004 WKN: 853849

Takeda

Takeda. ISIN: JP3463000004 WKN: 853849

Takeda

Das große EMFIS Marktupdate (EM Stock Picker No. 20)

Tokio: Takeda rutscht ab. Spekulation um Jahresüberschuß ...

Tokio: Takeda rutscht ab

EMFIS EM Stocks Review: Asien. Korea und Taiwan im Plus ...

EMFIS EM Stocks Review: Asien